Overview

Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes

Status:
Completed

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to find the highest tolerable dose of gimatecan that can be given to treat myelodysplastic syndrome (MDS).

Phase:

Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Novartis

Treatments:

Camptothecin